06-229
Anti-phospho-erbB-2/HER-2 (Tyr1248) Antibody
Upstate®, from rabbit
Synonym(s):
CD340 antigen, MLN 19, NEU proto-oncogene, Tyrosine kinase-type cell surface receptor HER2, c-erb B2/neu protein, neuroblastoma/glioblastoma derived oncogene homolog, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (neuro/glioblastoma der
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
rabbit
Quality Level
antibody form
affinity purified immunoglobulin
antibody product type
primary antibodies
clone
polyclonal
purified by
affinity chromatography
species reactivity
human, rat
packaging
antibody small pack of 25 μL
manufacturer/tradename
Upstate®
technique(s)
immunocytochemistry: suitable
western blot: suitable
isotype
IgG
NCBI accession no.
UniProt accession no.
shipped in
ambient
target post-translational modification
phosphorylation (pTyr1248)
Gene Information
human ... ERBB2(2064)
General description
The ErbB-2 proto-oncogene, also called Neu, EGFR-2 or HER-2, is a member of the transmembrane receptor tyrosine kinase family, which also includes EGF receptor and EGFR-3 (HER-3 or ErbB-3). Although, ErbB-2 does not have any known high-affinity ligands, its kinase activity can be activated without ligand by either overexpression or heteroassociation with other members of the ErbB family. Amplification of the ErbB-2 gene and overexpression of its product has been detected in almost 40% of primary human breast tumors, which correlates with poor prognosis in node positive breast cancer. ErbB-2 overexpression is also observed in ovarian, gastric, salivary and non-small cell lung carcinomas. Because of this, ErbB-2 is one of the major drug targets for breast cancer and other cancer treatments.
Specificity
Predicted to cross react with rat based on conservation of immunogenic sequence.
Recognizes and is specific for the activated form of erbB-2/HER-2 oncoprotein, MW ~138 kDa.
Immunogen
Epitope: Tyr1248
Synthetic phosphopeptide, residues 1243-1255, corresponding to a major auto-phosphorylation (Tyr1248) site of human erbB-2/HER-2 (C-AENPEpYLGLDVPV).
Application
Immunohistochemistry:
IHC was performed by an independent laboratory.
Immunocytochemistry:
2 µg/mL of a previous lot showed positive immunostaining for phospho-erbB2/HER-2 in EGF treated A431 cells.
IHC was performed by an independent laboratory.
Immunocytochemistry:
2 µg/mL of a previous lot showed positive immunostaining for phospho-erbB2/HER-2 in EGF treated A431 cells.
Research Category
Signaling
Signaling
Research Sub Category
Growth Factors & Receptors
Kinases & Phosphatases
Growth Factors & Receptors
Kinases & Phosphatases
This Anti-phospho-erbB-2/HER-2 (Tyr1248) Antibody is validated for use in IC, WB for the detection of phospho-erbB-2/HER-2 (Tyr1248).
Quality
Evaluated by Western Blot on A431+/-EGF lysates.
Western Blotting Analysis:
1:1000 dilution of this antibody detected phospho-erbB2/Her2 on 10 µg of A431+EGF lysates.
Western Blotting Analysis:
1:1000 dilution of this antibody detected phospho-erbB2/Her2 on 10 µg of A431+EGF lysates.
Target description
185 kDa
Physical form
Double immunoaffinity purified rabbit polyclonal IgG in buffer containing 0.1M Tris-Glycine, 0.15M NaCl, 0.05% Sodium Azide, pH7.4
ImmunoAffinity Purified
Storage and Stability
Stable for 1 year at -20ºC from date of receipt.
Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Analysis Note
Control
EGF treated A431 cells
EGF treated A431 cells
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models.
Longo, Sharon L, et al.
Investigational New Drugs, 30, 2161-2172 (2012)
Tonghui Wang et al.
Cancer science, 108(4), 671-677 (2017-02-07)
It is well documented that human epidermal growth factor receptor 2 (HER2) overexpression/amplification is associated with poor survival in breast cancer patients. However, it is largely unknown whether HER2 somatic mutations are associated with survival in HER2-negative breast cancer patients.
Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines.
DeArmond, D; Brattain, MG; Jessup, JM; Kreisberg, J; Malik, S; Zhao, S; Freeman, JW
Oncogene null
BIBX1382BS, but not AG1478 or PD153035, inhibits the ErbB kinases at different concentrations in intact cells.
M Egeblad, O H Mortensen, L C van Kempen, M Jaattela
Biochemical and biophysical research communications null
Anneleen Daemen et al.
Breast cancer research : BCR, 20(1), 8-8 (2018-02-01)
Approximately one in five breast cancers are driven by amplification and overexpression of the human epidermal growth factor receptor 2 (HER2) receptor kinase, and HER2-enriched (HER2E) is one of four major transcriptional subtypes of breast cancer. We set out to
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service